Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.…
…
Illumina hat sich als Schlüsselspieler in der Genomforschung etabliert und prägt mit seinen Technologien die Möglichkeiten der modernen Medizin.…
Little Rock (www.aktiencheck.de) - Illumina-Aktienanalyse von Stephens Inc.:
1. Anpassung des Kursziels und Übergewichtung
Stephens Inc. hat das Kursziel für die Aktie…
…
Milwaukee (www.aktiencheck.de) - Rating-Update:
Die Analysten von Robert W. Baird stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…
…
Illuminas third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.…
Illumina shares fall 5% as Q4 revenue guidance disappoints…
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing…
Reaching a new one-year high, Illumina remains in investors sight owing to its strong strategic execution and positive growth outlook.…
Die Aktie von Illumina (ILMN) könnte jetzt den Boden nachhaltig verlassen. Es handelt sich um ein Unternehmen im Bereich der Genomik,…
London (www.aktiencheck.de) - Rating-Update:
Barclays stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) weiterhin mit…
Toronto (www.aktiencheck.de) - Illumina-Aktienanalyse von RBC Capital Markets:
Aktuelle Bewertung
RBC Capital bleibt optimistisch in Bezug auf Illumina Inc. (ISIN: US4523271090, WKN:…
Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day.…
The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…
Düsseldorf (www.aktiencheck.de) - Illumina-Chartanalyse von HSBC Trinkaus & Burkhardt:
Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…
Plus, corporate failures hit the cleantech industry and the EU’s top court sides with Illumina after a probe into $8bn…
Top EU court sides with U.S. biotech group Illumina in Grail legal battle…
EU top court backs Illumina fight against EU probe into Grail deal…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Argus Research stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…
DaVita and Illumina are included in this Analyst Blog.…
…
Illuminas cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted…
…
According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…
…
Düsseldorf (www.aktiencheck.de) - Illumina-Chartanalyse von HSBC Trinkaus & Burkhardt:
Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…
Illumina shares gain after TD Cowen upgrade…
Illuminas (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.…
New CRO and SVP Bring Deep Experience in Advertising, Agencies and Brands New CRO and SVP Bring Deep Experience in…
…
Illumina expects full-year sales from core segment to decline on biotech funding crunch…
Keinen Grund zur Freude haben die Investoren von Illumina : Der Titel verbilligt sich am Freitag deutlich. Der Anteilsschein von…
Die Aktie von Illumina zählt am Donnerstag zu den großen Gewinnern an der Börse. Das Wertpapier verteuert sich heute deutlich.…
The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after…
…
New York (www.aktiencheck.de) - Illumina-Aktienanalyse von der Citigroup:
Die Analysten der Citigroup stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN:…
By integrating Fluents unique technology with Illuminas (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a…
The Global Cancer Diagnostics Market Size was Valued at USD 140.25 Billion in 2023 and the Worldwide Cancer Diagnostics Market…
Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail…
Illumina to take $1.47 billion goodwill impairment charge related to Grail in Q2…
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to…
The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer…
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out…
Grail bets big on flagship cancer test after spin-off from Illumina…
The Global Nucleic Acid Isolation & Purification Market Size was Valued at USD 5.5 Billion in 2023 and the Worldwide…
New York (www.aktiencheck.de) - Rating-Update:
Guggenheim Securities stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN)…
The Global Companion Diagnostics Market Size was Valued at USD 7.12 Billion in 2023 and the Worldwide Companion Diagnostics Market…
Die Aktie von Illumina zählt am Mittwoch zu den großen Verlierern am Aktienmarkt. Das Papier verbilligt sich heute deutlich. Mit…